Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2013

SAFC, CatScI Team Up to Offer Catalysis Services

  • SAFC Commercial, Sigma-Aldrich's custom manufacturing services business unit, is now in a services agreement with U.K.-based catalysis company CatScI. SAFC says that their customers will now have access to new reactions, homogeneous and heterogeneous catalysis, biocatalysts, solvent selection and process development, in addition to metal removal, recovery and recycling services as a result of the new agreement.

    “As a combined offering, we are able to provide customers a single source for high-quality, high-value fundamental research, development, scale-up and manufacture, with additional process development resources for customers to screen projects more quickly, and efficiently maximize catalyst reactions using the appropriate ligands, solvents, and science,” said Andreas Weiler, head of Global Strategic Marketing for Contract Manufacturing Services & Solutions at SAFC, in a statement.

    Formed in late 2010, CatScI's facility in Cardiff was set up in 2011 after the company purchased 16 tons of scientific equipment following the reorganization of R&D within AstraZeneca and the closing of the research laboratories at Avlon. Back in April, they entered into a partnership agreement with SiliCycle to support the Canadian firm's development of supported catalysts and scavengers and to act as an agent for the company. SiliCycle develops, manufactures, and commercializes silica-based and specialty products for chromatography, analytical and organic chemistry.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »